e-learning
resources
Virtual 2020
Wednesday, 09.09.2020
Recent innovations regarding the mechanisms and treatments of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical trial: Impact of Probiotical® on asthma control and inflammation
C. Moermans (Liege, Belgium), S. Graff (Liege, Belgium), L. Medard (Liege, Belgium), F. Schleich (Liege, Belgium), V. Paulus (Liege, Belgium), F. Guissard (Liege, Belgium), M. Henket (Liege, Belgium), R. Louis (Liege, Belgium)
Source:
Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Session:
Recent innovations regarding the mechanisms and treatments of asthma
Session type:
Oral Presentation
Number:
5281
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Moermans (Liege, Belgium), S. Graff (Liege, Belgium), L. Medard (Liege, Belgium), F. Schleich (Liege, Belgium), V. Paulus (Liege, Belgium), F. Guissard (Liege, Belgium), M. Henket (Liege, Belgium), R. Louis (Liege, Belgium). Clinical trial: Impact of Probiotical® on asthma control and inflammation. 5281
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Aerobic training decrease bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: A randomized controlled trial
Source: International Congress 2014 – Best abstracts in pulmonary rehabilitation and exercise training
Year: 2014
Correlation between meteo-climatological factors and asthma exacerbation among children: A prospective study
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016
Detection of asthma patient-reported exacerbations during follow-up in the ASTROLAB cohort
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
First clinical trial of a new IgE-adsorber in allergic asthma
Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma
Year: 2015
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Evaluation of vitamin D in bronchial asthma and the effect of vitamin D supplementation on asthma severity and control: A randomised control trial
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Aerobic training decreases bronchial hyperresponsiveness, serum chemokines and symptoms in asthmatic patients: Randomized controlled trial
Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions
Year: 2013
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
The control of asthma in real life: Baseline evaluation of a long-term study
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study
Source: International Congress 2014 – COPD physiopathology
Year: 2014
4–year trajectory of medication adherence amongst severe asthma patients: Risk factors and impact on asthma control
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept